Dr. Oliver Sartor: The Prostate Cancer Group

Dr. Oliver Sartor is the clinical leader of the Prostate Cancer Group at Tulane, which has multiple areas of strength. The program encompasses the entire spectrum of the disease, from utilizing and developing novel early detection methods to putting into practice the most innovative treatments for advanced and refractory cancer cases.

The group manages approximately two-thousand cases, the largest number of any institution in the gulf south. The program is nationally recognized for its leadership in the implementation of clinical genetic testing, robotic surgery, and the management of advanced disease.

Additionally, for nearly a decade the program has been maintaining a prostate cancer tissue bank, with near universal patient consent and enrollment for cancer and matched tissue banking. This bank is unique in that it has patient samples from a wide variety of patient populations, many of which are typically under-represented and bear health disparity burdens.

This leading-edge clinical program is supported by robust collaborations with basic research scientists at Tulane, whose labs focuses on a wide variety of topics relevant to prostate cancer, including androgen receptor biology and exosome signaling in prostate cancer. The clinical and basic research components are further aligned and implemented through a robust clinical trials program.
Clinical Trials in Prostate Cancer

Tulane's prostate cancer program has a strong history of partnering with industry for clinical trials. Currently, there are 12 active clinical trials at Tulane related to prostate cancer. The treatment options under study in these trials include immunotherapy, radiotherapy, and Phase I agents.

With enrolled patients hailing from 26 states and 7 countries, the Prostate Cancer program at Tulane is nationally recognized for its expertise in trial design and execution, and Dr. Sartor continues to be highly sought after for his expertise in prostate cancer and drug trial administration by industry collaborators. Indeed, he has personally seen 5 agents for prostate cancer treatment acquire FDA approval, and has chaired four committees granting approval to additional treatment options.

This clinical trial experience and expertise makes The Tulane Prostate Cancer Group an attractive collaborator for industry – not just for the more traditional non-profit, academic and foundation research relationships. With its complimentary patient-centered and basic research components, this group is a world-class entity with a comprehensive expertise in prostate cancer – spanning bench, translational, and clinical research.

Contact and Further Information:
James R Zanewicz
Chief Business Officer
zanewicz@tulane.edu

Find Us:
engage.tulane.edu
t: @zanewicz
t: @engagetulane